Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178098 · ClinicalTrials.gov registry record · Phase 2
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
A Phase 2 study of Hypertension and Hypercholesterolemia, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
- 20
- Study locations
NCT02178098: Completed Phase 2 study of Hypertension and Hypercholesterolemia, sponsored by Esperion Therapeutics.
NCT02178098 is a Phase 2 study of Hypertension and Hypercholesterolemia that has completed, run by Esperion Therapeutics. The registered enrollment target is 143 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02178098, a Phase 2 study of Hypertension and Hypercholesterolemia, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.
Primary Outcome
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value. For the Week 6 endpoint, missing values at Week 6 were imputed usi
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ETC-1002
Study Locations (20)
Florida
- - DeLand
- - Fort Lauderdale
- - Hialeah
- - Oviedo
- - Pembroke Pines
- - Pembroke Pines
- - Port Orange
Alabama
- - Birmingham
- - Muscle Shoals
Arizona
- - Chandler
- - Glendale
Illinois
- - Chicago
- - Gurnee
California
- - Los Angeles
Idaho
- - Meridian
Indiana
- - Indianapolis
Kentucky
- - Paducah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2014-06-16 |
| Est. Completion | 2015-05-22 |
| Phase | Phase 2 |
What the finished NCT02178098 record still lists
NCT02178098 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02178098 names 20 study sites across 11 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT02178098 about?
NCT02178098 is a clinical study titled "Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension". This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.
What is the current status of trial NCT02178098?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2014-06-16. Estimated completion is 2015-05-22.
What conditions does trial NCT02178098 study?
This clinical trial studies the following conditions: Hypertension, Hypercholesterolemia.
What interventions are being tested in trial NCT02178098?
The interventions under investigation include: Placebo (DRUG), ETC-1002 (DRUG).
Who is sponsoring clinical trial NCT02178098?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02178098 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02178098's enrollment target sits among peer trials
143 258th of 470 higher than 213 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI